Lo Kevin Bryan, Dayanand Sandeep, Ram Pradhum, Dayanand Pradeep, Slipczuk Leandro N, Figueredo Vincent M, Rangaswami Janani
Department of Medicine, Einstein Medical Center, Philadelphia, PA, United States.
Department of Cardiology, Einstein Medical Center, Philadelphia, PA, United States.
Curr Cardiol Rev. 2019;15(2):76-82. doi: 10.2174/1573403X14666181024155247.
Percutaneous mitral valve repair is emerging as a reasonable alternative especially in those with an unfavorable surgical risk profile in the repair of mitral regurgitation. At this time, our understanding of the effects of underlying renal dysfunction on outcomes with percutaneous mitral valve repair and the effects of this procedure itself on renal function is evolving, as more data emerges in this field. The current evidence suggests that the correction of mitral regurgitation via percutaneous mitral valve repair is associated with some degree of improvement in cardiac function, hemodynamics and renal function. The improvement in renal function was more significant for those with greater renal dysfunction at baseline. The presence of Chronic Kidney Disease (CKD) in turn has been associated with poor long-term outcomes including increased mortality and hospitalization among patients who undergo percutaneous mitral valve repair. This was true regardless of the degree of improvement in GFR post repair advanced CKD. The adverse impact of CKD on long-term outcomes was consistent across all studies and was more prominent in those with GFR<30 mL/min/1.73 m². It is clear that from these contrasting evidences of improved renal function post mitral valve repair but poor long-term outcomes including increased mortality in patients with CKD, that proper patient selection for percutaneous mitral valve repair is key. There is a need to have better-standardized criteria for patients who should qualify to have percutaneous mitral valve replacement with Mitraclip. In this new era of percutaneous mitral valve repair, much work needs to be done to optimize long-term patient outcomes.
经皮二尖瓣修复术正逐渐成为一种合理的替代方案,尤其是对于那些二尖瓣反流修复手术风险较高的患者。目前,随着该领域更多数据的出现,我们对潜在肾功能不全对经皮二尖瓣修复术预后的影响以及该手术本身对肾功能的影响的认识也在不断发展。目前的证据表明,通过经皮二尖瓣修复术纠正二尖瓣反流与心脏功能、血流动力学和肾功能的一定程度改善相关。对于基线肾功能不全程度较重的患者,肾功能改善更为显著。慢性肾脏病(CKD)的存在反过来又与经皮二尖瓣修复术患者的不良长期预后相关,包括死亡率增加和住院率增加。无论修复后肾小球滤过率(GFR)改善程度如何,晚期CKD患者均如此。CKD对长期预后的不利影响在所有研究中都是一致的,在GFR<30 mL/min/1.73 m²的患者中更为突出。显然,从二尖瓣修复术后肾功能改善但包括CKD患者死亡率增加在内的不良长期预后的这些相互矛盾的证据来看,经皮二尖瓣修复术的恰当患者选择是关键。需要为有资格接受Mitraclip经皮二尖瓣置换术的患者制定更好的标准化标准。在经皮二尖瓣修复术的这个新时代,需要做很多工作来优化患者的长期预后。